Solanezumab, Gantenerumab Fail to Slow Alzheimer Progression, But DIAN-TU Trial Sheds Positive Light
April 6th 2020Despite solanezumab (Eli Lilly) and gantenerumab (Roche and Genentech) failing to meet the DIAN-TU trial primary end point in inherited Alzheimer disease, the international undertaking provided some positive takeaways for the clinical community.
Compulsive Behaviors May Be More Likely in Parkinson Disease Dementia
April 5th 2020A multicenter, cross-sectional, observational, Spanish nationwide study’s findings suggest that those with Parkinson disease dementia may be predisposed to impulse control disorder symptoms and related behaviors.